When comparing pCR rates across different molecular subtypes, it was observed that HER2-negative tumors represented a small proportion of tumors with pCR.(17) This can be partially explained by the high prevalence of HER2-positive tumors in our sample (64.4%) compared to the expected distribution of molecular subtypes in breast cancer.(18) Due to this selection bias, the assessment of the response stratified by the other molecular subtypes was limited. The gene discussed is ERBB2; the disease is breast carcinoma.